Gino In * USC Profiles

Gino In

Title(s)	Assistant Professor of Clinical Medicine
Phone	+1 323 226 7622
vCard	Download vCard

Biography

Education and Training

University of Southern California, Los Angeles, CA	Fellowship	2016	Hematology/Oncology
SUNY Downstate Medical Center, Brooklyn, NY	Residency	2011	Internal Medicine
SUNY Downstate Medical Center, Brooklyn, NY	Internship	2010
Ross University, North Brunswick Township, NJ	MD	2010	Medicine
Emory University, Atlanta, GA	MPH	2006	Environmental/Occupational Health
Emory University, Atlanta, GA	BS	2002

Awards and Honors

University of Southern California

Chief Medical Oncology Fellow

Overview

Gino K. In, MD, MPH, is a medical oncologist who specializes in solid tumor and cutaneous oncology. He completed his fellowship training in hematology and oncology at the University of Southern California, Keck School of Medicine, where he was the chief medical oncology fellow. He subsequently joined the USC Norris Comprehensive Cancer Center, and now serves as Assistant Professor of Clinical Medicine in the Division of Oncology, and Assistant Professor of Dermatology. Dr. In’s research focus includes the multi-disciplinary management of melanoma and other skin cancers, including cutaneous squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma. He has a specific interest in non-UV related melanoma subtypes and intratumoral therapies. Dr. In is the lead primary investigator for cutaneous oncology clinical trials at USC, including studies through the National Cancer Institute, California Cancer Consortium, and Southwest Oncology Group.

Interests

Medical Oncology, Skin Cancer, Melanoma, Acral Lentiginous Melanoma, Uveal Melanoma, Mucosal Melanoma, Squamous Cell Carcinoma, Basal Cell Carcinoma, Merkel Cell Carcinoma, Dermatofibrosarcoma Protuberans, Porocarcinoma

Bibliographic

Publications

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.

List All | Timeline

Gatalica Z, Vranic S, Krušlin B, Poorman K, Stafford P, Kacerovska D, Senarathne W, Florento E, Contreras E, Leary A, Choi A, In GK. Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease. Cancer Med. 2020 Jan 03. PMID: 31899853.

View in: PubMed
Miller KA, Wojcik KY, Cockburn MG, In GK, Hamilton AS, Milam JE. Prevalence and correlates of adherence to skin examination among adolescent and young adult survivors of melanoma from the Project Forward Study. Pediatr Blood Cancer. 2019 Nov 27; e28090. PMID: 31774240.

View in: PubMed
Vaidya P, Mehta A, Ragab O, Lin S, In GK. Concurrent radiation therapy with programmed cell death protein 1 inhibition leads to a complete response in advanced cutaneous squamous cell carcinoma. JAAD Case Rep. 2019 Sep; 5(9):763-766. PMID: 31516991.

View in: PubMed
Adler BL, Smogorzewski J, Sierro T, Shauly O, Osipchuk D, Miller M, Mert M, Fong MW, Ganesh S, Han H, In GK, Maw TT, Smogorzewski M, Hu J, Ngo B, Lee D, Ahronowitz I. Skin cancer and dermatoses in a majority Hispanic population of solid organ transplant recipients. J Am Acad Dermatol. 2019 Aug 07. PMID: 31400454.

View in: PubMed
Snow A, Ricker C, In GK. Two synchronous malignancies: nodular melanoma and renal cell carcinoma in a patient with an underlying germline BRCA2 mutation. BMJ Case Rep. 2019 Jun 20; 12(6). PMID: 31227566.

View in: PubMed
Li S, Song Y, Quach C, Guo H, Jang GB, Maazi H, Zhao S, Sands NA, Liu Q, In GK, Peng D, Yuan W, Machida K, Yu M, Akbari O, Hagiya A, Yang Y, Punj V, Tang L, Liang C. Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. Nat Commun. 2019 04 12; 10(1):1693. PMID: 30979895.

View in: PubMed
Trodello C, Higgins S, Ahadiat O, Ragab O, In G, Hawkins M, Wysong A. Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis From a Single Tertiary Academic Medical Center. Dermatol Surg. 2019 02; 45(2):254-267. PMID: 30672860.

View in: PubMed
Lara KM, In GK, Matcuk GR, Mehta A, Hu JS. Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma. JAAD Case Rep. 2018 Nov; 4(10):1004-1006. PMID: 30450405.

View in: PubMed
Nazemi A, Higgins S, Swift R, In G, Miller K, Wysong A. Eccrine Porocarcinoma: New Insights and a Systematic Review of the Literature. Dermatol Surg. 2018 10; 44(10):1247-1261. PMID: 29894433.

View in: PubMed
In G, Mason J, Lin S, Newton PK, Kuhn P, Nieva J. Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer. Converg Sci Phys Oncol. 2017 Sep; 3(3). PMID: 30283700.

View in: PubMed
In GK, Mason J, Lin S, Newton P, Kuhn P, Nieva J.Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer. Convergent Science Physical Oncology. 2017; 3(3).
Miller KA, In GK, Jiang SY, Ahadiat O, Higgins S, Wysong A, Cockburn MG.Skin Cancer Prevention Among Hispanics: a Review of the Literature. Epidemiology. 2017.
In GK, Hu JS, Tseng WW. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Aug; 9(8):533-550. PMID: 28794805.

View in: PubMed
In GK, Nieva J.Emerging Chemotherapy Agents in Lung Cancer: Nanoparticle Therapeutics for Non-Small Cell Lung Cancer. Transl Cancer Res. 2015; 4(4):340-355.

View Publication
In G, Dorff T. Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors: Current Concepts and Controversies. Urol Clin North Am. 2015 Aug; 42(3):347-57. PMID: 26216822.

View in: PubMed